Education
About Us
Working with TipRanks
Follow Us
Lytix Biopharma AS (DE:6BG)
:6BG
6BG Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.40 - €1.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€28.64M
Enterprise Value€262.91M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
May 15, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding68,262,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)187.69
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Lytix Biopharma AS News
PremiumCompany Announcements
Lytix Biopharma’s LTX-315 Shows Promising Results as It Eyes Phase III Trials
PremiumCompany Announcements
Lytix Biopharma Secures U.S. Patent for Cancer TherapyPremiumCompany Announcements
Lytix Biopharma to Announce Q4 2024 Financial ResultsPremiumCompany Announcements
Lytix Biopharma’s LTX-315 Shows Promising Results in BCC Treatment
PremiumCompany Announcements
Lytix Biopharma Completes Capital Raise of NOK 111.3 Million
PremiumCompany Announcements
Lytix Biopharma Halts Additional Share Offering After Successful FundraisingPremiumCompany Announcements
Lytix Biopharma Secures NOK 111.3 Million Funding
PremiumCompany Announcements
Lytix Biopharma Increases Capital for Cancer Innovations---
6BG FAQ
What was Lytix Biopharma AS’s price range in the past 12 months?
Lytix Biopharma AS lowest stock price was €0.40 and its highest was €1.04 in the past 12 months.
What is Lytix Biopharma AS’s market cap?
Lytix Biopharma AS’s market cap is €28.64M.
When is Lytix Biopharma AS’s upcoming earnings report date?
Lytix Biopharma AS’s upcoming earnings report date is May 15, 2025 which is in 72 days.
How were Lytix Biopharma AS’s earnings last quarter?
Lytix Biopharma AS released its earnings results on Feb 13, 2025. The company reported -€0.046 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.046.
Is Lytix Biopharma AS overvalued?
According to Wall Street analysts Lytix Biopharma AS’s price is currently Overvalued.
Does Lytix Biopharma AS pay dividends?
Lytix Biopharma AS does not currently pay dividends.
What is Lytix Biopharma AS’s EPS estimate?
Lytix Biopharma AS’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lytix Biopharma AS have?
Lytix Biopharma AS has 68,262,000 shares outstanding.
What happened to Lytix Biopharma AS’s price movement after its last earnings report?
Lytix Biopharma AS reported an EPS of -€0.046 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lytix Biopharma AS?
Currently, no hedge funds are holding shares in DE:6BG
---
Company Description
Lytix Biopharma AS
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its lead product, LTX-315, is an oncolytic peptide with the potential to personalize immunotherapy.
---
Technical Analysis
---